Ann: Rare Earth Results and Tenement Expansion, page-16

First 16 Last

Share
Profile

Follow
1st

1,609 Posts.

410

16/01/24

10:43

Post #: 71898009
Share

Originally posted by mr.robert: ↑

Why thank you so much for the welcome. I am bemused by your response. Please don’t take my opinion personally, I have only stated the state of the current REE play and not as you suggest here to shade CR9. So in my opinion, because this is what HC is for and as a shareholder I’m entitled to have one, the HPA game is going nowhere. There are no companies competing for our product through an off take agreement. Why is this? I suspect because no one has a fully functioning facility capable of processing commercial quantities of kaolin. If there was, the front end loaders would be filling that empty shed as we speak. So if CR9 can flip into REE then good. The announcement yesterday indicated the samples came from rock chips. Now that is a different world from the ionic clay REEs that other players have, particularly when it comes to Capex. But I’m sure you already know that.

I’ve always viewed you posts with interest as you appear to have sound knowledge in the kaolin sphere and have been less “reactive” to other people’s opinions then some others in here. So hence my bemusement with your response. I suspect and understandably so, that you may be ‘knee deep” or further in CR9 and that would make one slightly sensitive. But as mentioned nothing personal, just my opinion.

Good luck to all holders. If CR9 can pull this off then we all benefit.

Expand

Thought you could have come up with a better moniker than mr. robert, wiffy.

Last edited by 1st: 16/01/24

CR9 Price at posting: 2.7¢ Sentiment: Buy Disclosure: Held
3 Upvote

1 Great analysis

Reply

Top Stories

PCK

PainChek close to finding out if FDA approves its flagship app for use in dementia care

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

FRB

Firebird achieves preliminary approvals for its Jinshi plant design

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

There are more pages in this discussion • 34 more messages in this thread...

First 16 Last

Add CR9 (ASX) to my watchlist

(20min delay)
Last 0.9¢		Change 0.001(12.5%)		Mkt cap ! $3.720M

Open	High	Low	Value	Volume
0.9¢	0.9¢	0.9¢	$2.444K	271.5K

Buyers (Bids)

No.	Vol.	Price($)
1	81761	0.9¢

Sellers (Offers)

Price($)	Vol.	No.
1.0¢	200000	1

View Market Depth

No.	Vol.	Price($)
1	81761	0.009
6	2003235	0.008
4	1080032	0.007
2	400000	0.005
3	1347512	0.004

Price($)	Vol.	No.
0.010	200000	1
0.011	100000	1
0.012	196405	3
0.015	24871	1
0.027	56338	1

Last trade - 10.02am 02/10/2024 (20 minute delay)

CR9 (ASX) Chart

Ann: Rare Earth Results and Tenement Expansion, page-16

PainChek close to finding out if FDA approves its flagship app for use in dementia care

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Firebird achieves preliminary approvals for its Jinshi plant design

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Rare Earth Results and Tenement Expansion, page-16

Top Stories

PainChek close to finding out if FDA approves its flagship app for use in dementia care

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Firebird achieves preliminary approvals for its Jinshi plant design

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News